ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ramucirumab

Also written as “IMC-1121B (ramucirumab)”, “Ramucirumab (IMC-1121B)” and “IMC-1121B”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Breast Neoplasms, led by 6 companies.

Drug pageRamucirumab: every studyMany companies study it; this page follows only the 58 they lead. All 109 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jun 20, 200858 company-led studies, 5 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly533 open or runningphase 3since Jun 20, 2008Aug 13, 2007May 2027phase 2 · NCT05999994
Arog Pharmaceuticalsits history only10 open or runningphase 1since Jun 14, 2017Jun 14, 2017none ahead
AstraZenecaits history only11 open or runningphase 2since May 5, 2025May 5, 2025Feb 23, 2029phase 2 · NCT06996782
Innovent Biologicsits history only10 open or runningphase 3since Dec 3, 2020Dec 3, 2020none ahead
Merckits history only11 open or runningphase 2since May 31, 2024May 31, 2024May 9, 2028phase 2 · NCT06445972
Sino Biopharmaceuticalits history only10 open or runningphase 1since Mar 24, 2023Mar 24, 2023none ahead

Also a collaborator on its studies: Daiichi Sankyo and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 38 studies since Aug 13, 2007.

  1. May 1, 2015Phase 3 study in Carcinoma, HepatocellularNCT02435433 · 399 enrolled · United States, Australia, Austria and more
  2. May 11, 2015Phase 1 study in Carcinoma, Non-Small-Cell LungNCT02443324 · 175 enrolled · United States, France, Germany and more
  3. May 12, 2015Phase 2 study in Stomach NeoplasmsNCT02443883 · 164 enrolled · United States, Argentina, Australia and more
  4. Jul 31, 2015Phase 2 study in Stomach NeoplasmsNCT02514551 · 245 enrolled · United States, Belgium, Canada and more
  5. Aug 31, 2015Phase 2 study in Metastatic Gastric AdenocarcinomaNCT02539225 · 191 enrolled · Japan, Korea, Republic of, Taiwan
  6. Sep 25, 2015Phase 1 study in NeoplasmsNCT02564198 · 29 enrolled · United States
  7. Mar 14, 2016Phase 2 study in Biliary Tract NeoplasmsNCT02711553 · 309 enrolled · United States, Argentina, Australia and more
  8. May 31, 2016Phase 1 study in Carcinoma, Non-Small-Cell LungNCT02789345 · 29 enrolled · United States, France, Korea, Republic of and more
  9. Jul 11, 2016Phase 2 study in Carcinoma, Non-Small-Cell LungNCT02831491
  10. Sep 8, 2016Phase 3 study in Gastroesophageal Junction AdenocarcinomaNCT02898077 · 440 enrolled · China, Malaysia, Philippines and more
  11. Oct 29, 20192 phase 2 studiesNCT04145700, NCT04145349
  12. Jul 30, 2020Phase 1 study in HealthyNCT04495478 · 50 enrolled · United States
  13. Sep 16, 2020Phase 1 study in Advanced Solid TumorNCT04557384 · 3 enrolled · United States, Japan
  14. Aug 14, 2023Phase 2 study in NeoplasmsNCT05999994 · 105 planned · United States, Australia, Belgium and more

Ahead

  1. May 2027Primary completion: phase 2 study in NeoplasmsNCT05999994

TargetBeta

KDR →read by rule
“A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity”NCIt, by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule

Other programs on KDR

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
cabozantinibruleExelixisphase 436
apatinibruleJiangsu HengRui Medicinephase 347
AxitinibrulePfizerphase 345
anlotinibruleSino Biopharmaceuticalphase 340
vorolanibruleBetta Pharmaceuticalsphase 324
zanzalintinibruleExelixisphase 317
chiauranibruleChipscreen Biosciencesphase 315
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleadvenchen-laboratories-nanjing-ltdphase 38
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37

Studies

All 53 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05999994Neoplasms · United States, Australia, Belgium and more2RecruitingMay 2027105
NCT04557384Advanced Solid Tumor · United States, Japan1TerminatedMay 25, 20213
NCT04495478Healthy · United States1CompletedMay 9, 202150
NCT04145700Sarcoma, Synovial · United States, Australia, Belgium and more2TerminatedFeb 23, 202323
NCT04145349Desmoplastic Small Round Cell Tumor · United States, Australia, Germany and more2CompletedJun 14, 202430
NCT02898077Gastroesophageal Junction Adenocarcinoma · China, Malaysia, Philippines and more3CompletedJun 30, 2020440
NCT02831491Carcinoma, Non-Small-Cell Lung2WithdrawnJul 20170
NCT02789345Carcinoma, Non-Small-Cell Lung · United States, France, Korea, Republic of and more1CompletedOct 19, 201729
NCT02711553Biliary Tract Neoplasms · United States, Argentina, Australia and more2Active, not recruitingFeb 16, 2018309
NCT02564198Neoplasms · United States1CompletedJul 16, 201929
NCT02539225Metastatic Gastric Adenocarcinoma · Japan, Korea, Republic of, Taiwan2CompletedOct 25, 2017191
NCT02514551Stomach Neoplasms · United States, Belgium, Canada and more2CompletedOct 27, 2017245
NCT02443883Stomach Neoplasms · United States, Argentina, Australia and more2CompletedNov 18, 2016164
NCT02443324Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more1CompletedAug 31, 2018175
NCT02435433Carcinoma, Hepatocellular · United States, Australia, Austria and more3CompletedMar 15, 2018399
NCT02426125Carcinoma, Transitional Cell · United States, Australia, Belgium and more3CompletedApr 21, 2017530
NCT02411448Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more3Active, not recruitingJan 23, 2019545
NCT02314117Metastatic Gastric Adenocarcinoma · United States, Argentina, Belgium and more3CompletedJan 17, 2017645
NCT02082210Liver Neoplasms · United States2CompletedDec 5, 201797
NCT02079636Carcinoma, Non-Small-Cell Lung · United States, Spain1CompletedMay 2, 2018142
NCT02069041Carcinoma, Hepatocellular · Taiwan1CompletedSep 20168
NCT01983878Stomach Neoplasms · Japan2CompletedJan 201536
NCT01703091Non-small Cell Lung Cancer Metastatic · Japan2CompletedDec 2014197
NCT01682135Solid Tumor · China1CompletedMar 201528
NCT01634555Solid Tumors · United States2CompletedAug 201329
NCT01567163Malignant Solid Tumor · United States2CompletedDec 201222
NCT01515306Malignant Solid Tumor · United States2CompletedMar 20, 201348
NCT01427933Breast Neoplasms · United States2CompletedSep 2013141
NCT01286818Colorectal Neoplasms · Japan1CompletedFeb 20126
NCT01282463Urethral Neoplasms · United States, Canada2CompletedFeb 2015148
NCT01256567Breast Neoplasms · Japan1CompletedNov 20127
NCT01253525Adenocarcinoma · Japan1CompletedOct 20116
NCT01246960Stomach Neoplasms · United States2CompletedSep 2013168
NCT01234402Breast Neoplasms · United States, Canada2CompletedOct 2013153
NCT01183780Colorectal Neoplasms · United States, Argentina, Australia and more3CompletedJul 17, 20141,072
NCT01170663Stomach Neoplasms · United States, Argentina, Australia and more3CompletedJul 2013665
NCT01168973Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3CompletedDec 20131,253
NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2CompletedJan 2014280
NCT01140347Carcinoma, Hepatocellular · United States, Australia, Austria and more3CompletedMar 2014565
NCT01111604Colonic Neoplasms · United States, Canada2CompletedDec 2013158
NCT01017731Neoplasms · United States2CompletedApr 201068
NCT01005355Advanced Solid Tumors · Japan1CompletedFeb 201115
NCT00917384Stomach Neoplasms · United States, Argentina, Australia and more3CompletedJul 2012355
NCT00862784Colorectal Neoplasms · Canada, Spain2CompletedApr 201148
NCT00793975Neoplasms · United States1CompletedJun 200937
NCT00786383Neoplasms · United States1CompletedJan 200925
NCT00735696Carcinoma, Non-Small-Cell Lung · United States, United Kingdom2CompletedOct 201141
NCT00721162Ovarian Neoplasms · United States, United Kingdom2CompletedMay 201260
NCT00703326Breast Neoplasms · United States, Australia, Belgium and more3CompletedMar 31, 20131,144
NCT00683475Prostatic Neoplasms · United States2CompletedSep 2011138
NCT00627042Carcinoma, Hepatocellular · United States2CompletedMay 201142
NCT00533702Melanoma · United States2CompletedMay 2011106
NCT00515697Carcinoma, Renal Cell · United States2CompletedMay 201139

How it is read

Names in the registry

  • “Ramucirumab”, 36 entries
  • “IMC-1121B (ramucirumab)”, 4 entries
  • “Ramucirumab (IMC-1121B)”, 4 entries
  • “IMC-1121B”, 4 entries
  • “ramucirumab (IMC-1121B)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.